Vericel (VCEL) reported Q4 net income Thursday of $0.38 per diluted share, up from $0.26 a year earlier.
Analysts polled by FactSet expected $0.32.
Revenue for the quarter ended Dec. 31 was $75.4 million, up from $65.0 million a year earlier.
Analysts surveyed by FactSet expected $76.5 million.
For 2025, the biopharmaceutical company expects net revenue to increase 20% to 23%. Analysts polled by FactSet expect $289.8 million.
Additionally, the company said it had cash, restricted cash and investments of about $167 million as of Dec. 31, and no debt.
Vericel shares were down 4.7% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.